Phenomenex Chiral Screening Services Now Offered in China
News Dec 05, 2012
Phenomenex Inc. has announced the extension of its Chiral Screening Service to pharmaceutical and natural products customers in China.
The service is offered in collaboration with the Chinese Academy of Sciences (CAS), a leading academic and R&D center under which the Shanghai Institute of Organic Chemistry (SIOC) has developed a strong chiral team that works closely with Phenomenex.
The free Chiral Screening Service provides target screening using a library of HPLC columns including the Phenomenex Lux™ polysaccharide-based offerings, which demonstrate a success rate approaching 90 percent.
After resolving the chiral compound, Phenomenex delivers a method development and optimization plan to the customer within 10 business days - the same rapid turnaround the service promises in the U.S. and Europe.
“Our customer base in China has been growing rapidly and the expansion of our services will help us better serve them,” explains Michael Klein, brand manager for Phenomenex. “By teaming up with the CAS-SIOC, we are able to quickly roll out our rapid-response service.”
Enantiomers of chiral compounds may have different pharmacological effects in biological systems and they must be identified and evaluated separately.
“Resolving chiral compounds is relatively difficult, and column selection can be complicated,” continues Klein. “Our Chiral Screening Service eliminates time-consuming guesswork and also gives customers a chance to ‘test-drive’ our Lux columns.”
The Phenomenex team of chiral experts will customize a plan for each screening project, taking into account specific requirements and overall separation goals.
Once a project is completed, the customer will receive a report that details the optimal method including information on the chiral stationary phase (CSP) selected for the separation, running conditions and associated chromatograms.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018
18th International Conference and Exhibition on Analytical & Bioanalytical Chromatographic Techniques
Nov 02 - Nov 03, 2017